Posted by Michael Wonder on 07 Sep 2024
Axogen completes submission of biologics license application to US FDA for Avance Nerve Graft
6 September 2024 - Axogen announced that it has completed the rolling submission process for its biologics license application to the US FDA for Avance Nerve Graft.
Avance Nerve Graft previously received regenerative medicine advanced therapy designation from the FDA.
